A trial looking at ipilimumab for advanced non small cell lung cancer (IDEATE)
Cancer type:
Status:
Phase:
- spread to another part of the body
- come back after treatment
More about this trial
- carboplatin
- paclitaxel

Summary of results
- 479 people had ipilimumab, carboplatin and paclitaxel
- 477 people had a dummy drug (placebo), carboplatin and paclitaxel
- people who had ipilimumab, carboplatin and paclitaxel lived around 13 months after treatment
- people who had dummy drug, carboplatin and paclitaxel lived around 12 months after treatment
- a drop in the number of blood cells causing an increased risk of breathlessness, infection and bleeding
- diarrhoea
- decreased appetite
- skin rash and itching
- sickness
- tiredness (fatigue)
- numbness and tingling in fingers and toes

Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Christian Ottensmeier
Supported by
Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040